ImmunoMark London 2027: Immuno-Oncology & Biomarker Summit

ImmunoMark London 2027: Immuno-Oncology & Biomarker Summit is organized by Convolign Business Consulting and will be held from Mar 03 - 04, 2027 in London, England, United Kingdom.

Description:
The ImmunoMark Summit UK Edition returns for its second annual instalment, conceptualized and curated by Convolign Business Consulting. Building on the success of a landmark inaugural edition in 2026, the 2027 summit is larger, more ambitious, and shaped directly by the feedback of the community it serves.

As immunotherapies continue to reshape cancer care, from advanced CAR-T and TCR-T cell therapies to next-generation bispecific antibodies and AI-driven drug discovery, the identification and validation of clinically robust biomarkers has never been more central to oncology success.

Hosted in London, one of the world's foremost centres for life sciences innovation and oncology research, ImmunoMark Summit 2027 brings together pharmaceutical and biotech leaders, translational medicine experts, diagnostic developers, clinical researchers, and regulatory authorities from the UK, Europe, and beyond.

Why Attend:
Built for the People
Who Build the Field
Stay Ahead of the Science
Latest data, platform innovations, and pipeline insights from world-leading IO and biomarker researchers spanning cell therapies, AI biomarker discovery, and CDx commercialisation.

Build High-Value Connections
Network with 400+ senior decision-makers through structured 1:1 sessions, expert panel discussions, networking lunches, and a dedicated Day 1 Drinks and Cocktail Reception.

Access Expert Speaker Panel
Leaders from AstraZeneca, Roche, Merck, Johnson and Johnson, Novartis, GSK, and the UK's leading academic institutions presenting at the cutting edge of the field.

Gain Commercial Intelligence
Cross-functional panels bridging R&D, clinical, and commercial perspectives, covering reimbursement strategy, investment models, and the business of biomarker-driven oncology.